Myeloid-intrinsic cell cycle-related kinase drives immunosuppression to promote tumorigenesis

Jingying Zhou,Huanyu Wang,Ting Shu,Jing Wang,Weiqin Yang,Jingqing Li,Lipeng Ding,Man Liu,Hanyong Sun,John Wong,Paul Bo-san Lai,Shun-Wa Tsang,Simon E. Ward,King-Lau Chow,Joseph Jao-yiu Sung,Alfred Sze-Lok Cheng
DOI: https://doi.org/10.1016/j.isci.2023.107626
IF: 5.8
2023-08-01
iScience
Abstract:Massive expansion of immature and suppressive myeloid cells is a common feature of malignant solid tumors. Over-expression of cyclin-dependent kinase 20, also known as cell cycle-related kinase (CCRK), in hepatocellular carcinoma (HCC) correlates with reduced patient survival and low immunotherapy responsiveness. Beyond tumor-intrinsic oncogenicity, here we demonstrated that CCRK is upregulated in myeloid cells in tumor-bearing mice and in patients with HCC. Intratumoral injection of <i>Ccrk</i>-knockdown myeloid-derived suppressor cells (MDSCs) increased tumor-infiltrating CD8<sup>+</sup>T cells and suppressed HCC tumorigenicity. Using an indel mutant transgenic model, we showed that <i>Ccrk</i> inactivation in myeloid cells conferred a mature phenotype with elevated IL-12 production, driving Th1 responses and CD8<sup>+</sup>T cell cytotoxicity to reduce orthotopic tumor growth and prolong survival. Mechanistically, CCRK activates STAT3/E4BP4 signaling in MDSCs to acquire immunosuppressive activity through transcriptional IL-10 induction and IL-12 suppression. Taken together, our findings unravel mechanistic insights into MDSC-mediated immunosuppression and offer a therapeutic kinase-target for cancer immunotherapy.
multidisciplinary sciences
What problem does this paper attempt to address?